Pathogenicity of mutations discovered in BRCA1 BRCT domains is characterized by destabilizing the hydrophobic interactions

Journal of Cancer Science and Therapy

Volumn 4, Issue 11, 2012, Pages 386-393

  Badgujar, Dilip C ^a   Sawant, Ulka ^a   Mahadik, Hafiza ^a   Gadewal, Nikhil ^a   Varma, Ashok K ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

BRCA1 BRCT; Genetic counseling; Hydrophobic interactions; Pathogenicity; Targeted therapy

Indexed keywords

MUTANT PROTEIN;

ARTICLE; CHEMICAL INTERACTION; CIRCULAR DICHROISM; COMPUTER PROGRAM; CONTROLLED STUDY; ESCHERICHIA COLI; FLUORESCENCE SPECTROSCOPY; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENE THERAPY; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENOMIC INSTABILITY; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; LOSS OF FUNCTION MUTATION; MOLECULAR CLONING; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENICITY; PROTEIN DOMAIN; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; TUMOR SUPPRESSOR GENE;

EID: 84870747520     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000172     Document Type: Article

References (47)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71.
2. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, et al. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120-122.
3. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692-695.
4. Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, et al. (1996) Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 175: 738-746.
5. de Pauw A, Stoppa-Lyonnet D (2011) [Genetic consultation: hereditary cancer risk?]. Rev Prat 61: 538-541.
6. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, et al. (2010) The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 7: 708-717.
7. Katapodi MC, Northouse L, Pierce P, Milliron KJ, Liu G, et al. (2011) Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not. Oncol Nurs Forum 38: 572-581.
8. Barnes DR, A.C Antoniou (2012) Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers. J Intern Med 271: 331-343.
9. Shen D, Vadgama JV (1999) BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC). Oncol Res 11: 63-69.
10. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C, et al. (2012) Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4: 127ps10.
11. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
12. Malacrida S, Agata S, Callegaro M, Casella C, Barana D, et al. (2008) BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy. J Clin Oncol 26: 26-31.
13. Deng CX (2006) BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34: 1416-1126.
14. Starita LM, Parvin JD (2003) The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol 15: 345-350.
15. Williams RS, Green R, Glover JN (2001) Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 8: 838-842.
16. Zhang X, Moréra S, Bates PA, Whitehead PC, Coffer AI, et al. (1998) Structure of an XRCC1 BRCT domain: a new protein-protein interaction module. EMBO J 17: 6404-6411.
17. Derbyshire DJ, Basu BP, Serpell LC, Joo WS, Date T, et al. (2002) Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J 21: 3863-3872.
18. Singh N, Wiltshire TD, Thompson JR, Mer G, Couch FJ (2012) Molecular basis for the association of microcephalin (MCPH1) protein with the cell division cycle protein 27 (Cdc27) subunit of the anaphase-promoting complex. J Biol Chem 287: 2854-2862.
19. Birrane G, Varma AK, Soni A, Ladias JA (2007) Crystal structure of the BARD1 BRCT domains. Biochemistry 46: 7706-7712.
20. Rodriguez M, Yu X, Chen J, Songyang Z (2003) Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains. J Biol Chem 278: 52914-52918.
21. Shiozaki EN, Gu L, Yan N, Shi Y. (2004) Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. Mol Cell 14: 405-412.
22. Botuyan MV, Nominé Y, Yu X, Juranic N, Macura S, et al. (2004) Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. Structure 12: 1137-1146.
23. Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, et al. (2004) Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 11: 512-518.
24. Varma AK, Brown RS, Birrane G, Ladias JA (2005) Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex. Biochemistry 44: 10941-10946.
25. Shen Y, Tong L (2008) Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1. Biochemistry 47: 5767-5773.
26. Li S, Chen PL, Subramanian T, Chinnadurai G, Tomlinson G, et al. (1999) Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcriptionregulation of p21 is disrupted upon DNA damage. J Biol Chem 274: 11334-11338.
27. Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R (1998) The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem 273: 25388-25392.
28. Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, et al. (2007) Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316: 1194-1198.
29. Chen Y, Borowicz S, Fackenthal J, Collart FR, Myatt E, et al. (2006) Primary structure-based function characterization of BRCT domain replicates in BRCA1. Biochem Biophys Res Commun 345: 188-1896.
30. Plevova P, Hladikova A (2012) Genetic counselling in male carriers of BRCA1 and BRCA2 gene mutations. Klin Onkol 25: S67-73.
31. Halbert CH, Kessler L, Collier A, Weathers B, Stopfer J, et al. (2012) Low rates of african american participation in genetic counseling and testing for BRCA1/2 mutations: racial disparities or just a difference? J Genet Couns 21: 676-683.
32. Millot GA, Carvalho MA, Caputo SM, Vreeswijk MP, Brown MA, et al. (2012) A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat 33: 1526-1537.
33. Solyom S, Aressy B, Pylkäs K, Patterson-Fortin J, Hartikainen JM, et al. (2012) Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions. Sci Transl Med 4: 122-123.
34. Giannini G, Capalbo C, Ottini L, Buffone A, De Marchis L, et al. (2008) Clinical classification of BRCA1 DNA missense variants: H1686Q is a novel pathogenic mutation occurring in the ontogenetically invariant THV motif of the N-terminal BRCT domain. J Clin Oncol 26: 4212-4214.
35. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, et al. (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43: 295-305.
36. Thanassoulas A, Nomikos M, Theodoridou M, Yannoukakos D, Mastellos D, et al. (2010) Thermodynamic study of the BRCT domain of BARD1 and its interaction with the -pSER-X-X-Phe- motif-containing BRIP1 peptide. Biochim Biophys Acta 1804: 1908-1916.
37. Genoni A, Morra G, Colombo G (2012) Identification of domains in protein structures from the analysis of intramolecular interactions. J Phys Chem B 116: 3331-3343.
38. Patil R, Das S, Stanley A, Yadav L, Sudhakar A, et al. (2010) Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS One 5: e12029.
39. Brunet J, Vazquez-Martin A, Colomer R, Graña-Suarez B, Martin-Castillo B, et al. (2008) BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. Mol Carcinog 47: 157-163.
40. Moreau K, Dizin E, Ray H, Luquain C, Lefai E, et al. (2006) BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 281: 3172-3181.
41. Magnard C, Bachelier R, Vincent A, Jaquinod M, Kieffer S, et al. (2002) BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene 21: 6729-6739.
42. Williams RS, Lee MS, Hau DD, Glover JN (2004) Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol 11: 519-525.
43. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, et al. (2005) MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123: 1213-1226.
44. Mirkovic N, Marti-Renom MA, Weber BL, Sali A, Monteiro AN (2004) Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 64: 3790-3797.
45. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, et al. (2007) A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81: 873-883.
46. Iofrida C, Melissari E, Mariotti V, Guglielmi C, Guidugli L, et al. (2012) Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study. BMC Cancer 12: 207.
47. Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, et al. (2008) Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. Eur J Hum Genet 16: 820-832.